Company Filing History:
Years Active: 2021-2023
Title: Innovations of James Paul Broughton
Introduction
James Paul Broughton is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of programmable nuclease compositions. With a total of three patents to his name, Broughton is recognized for his innovative approaches to detecting target nucleic acids associated with various diseases.
Latest Patents
Broughton's latest patents focus on programmable nuclease compositions and methods of use. These patents describe devices, systems, fluidic devices, kits, and methods for the detection of target nucleic acids linked to diseases, cancers, genetic disorders, genotypes, phenotypes, or ancestral origins. The inventions include reagents of a guide nucleic acid that targets a specific nucleic acid, a programmable nuclease, and a single-stranded detector nucleic acid with a detection moiety. The target nucleic acid may indicate the presence of communicable diseases, cancers, or genetic disorders, as well as provide insights into genotypes, phenotypes, or ancestral origins.
Career Highlights
James Paul Broughton is currently employed at Mammoth Biosciences, Inc., where he continues to advance his research and development efforts. His work at the company has positioned him as a key player in the biotechnology sector, contributing to innovative solutions that address critical health challenges.
Collaborations
Broughton collaborates with talented individuals such as Lucas Benjamin Harrington and Janice Sha Chen. These partnerships enhance the creative and innovative processes within his projects, leading to impactful advancements in biotechnology.
Conclusion
James Paul Broughton is a distinguished inventor whose work in programmable nuclease compositions has the potential to revolutionize the detection of diseases and genetic disorders. His contributions to Mammoth Biosciences, Inc. and collaborations with fellow innovators underscore his commitment to advancing biotechnology.